Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma

Inclusion Criteria:

• Prior diagnosis of MM as defined according to IMWG criteria .

• Patients who are ineligible for participation in any ongoing clinical trial ofelranatamab, including lack of access due to geographical limitations, and who haveexhausted all other treatment options or experience lack of access to commerciallyavailable therapies due to geographical, financial or socioeconomic limitations.

• Measurable disease at screening based on IMWG criteria as defined by at least 1 ofthe following:

• Serum M-protein ≥0.5 g/dL (≥5 g/L)

• Urinary M-protein excretion ≥200 mg/24 hours

• Involved FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambdaFLC ratio (<0.26 or >1.65).

• Refractory to at least one IMiD, one PI, and one anti-CD38 antibody.

• Relapsed/refractory to last anti-MM regimen.

• ECOG performance status 0-1.

• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1.

• Not pregnant, willing to use contraception

Exclusion Criteria:

• Smoldering MM; plasma cell leukemia; POEMS syndrome; Waldenström'smacroglobulinemia; amyloidosis; stem cell transplant within 12 weeks prior toenrollment or active GVHD

• Previous treatment with BCMA directed therapy;

• Active HBV, HCV, SARS- CoV-2, HIV or any active, uncontrolled bacterial, fungal, orviral infection.

Active infections must be resolved at least 14 days prior to enrollment.

• Any other active malignancy within 3 years prior to enrollment, except foradequately treated basal cell or squamous cell skin cancer, carcinoma in situ orStage 0/1 with minimal risk of recurrence per treating physician.

• Previous administration with an investigational drug or vaccine within 30 days (oras determined by the local requirement) or 5 half-lives preceding the first dose ofstudy intervention used in this study (whichever is longer)